In the LIBRETTO-001 trial, it achieved an ORR of 64% (95% CI, 54–73) and a median DOR of 17.5 months (95% CI, 12.0–NE) in patients with advanced RET-fusion NSCLC. The gene discussed is RET; the disease is non-small cell lung carcinoma.